Trauma, Wound Care, and Emergency Medicine Technology – Impacts in Maryland Dive into Baltimore’s shock trauma and emergency medicine technology ecosystem in a two-part series. Learn about the technologies that [….]
Gain Therapeutics made its debut on the Nasdaq Thursday with a $40 million initial public offering. The company will use the funds to advance the development of its pipeline of therapeutics for rare genetic diseases characterized by protein misfolding.
Gain Therapeutics and the University of Maryland School of Medicine forged a research collaboration to investigate Gain’s structurally targeted allosteric regulators (STARs) in cellular models of neuronopathic Gaucher disease (nGD) and Parkinson’s disease (PD).